- Raw materials
- Antifibrotic agents
- Hydronidone
Hydronidone API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Hydronidone | CAS No: 851518-71-3 | GMP-certified suppliers
A medication that demonstrates antifibrotic potential for treating liver diseases involving fibrotic progression, currently available for investigational and research use.
Therapeutic categories
Primary indications
- Investigated for use/treatment in liver disease
Product Snapshot
- Hydronidone is an oral small molecule formulation under investigation
- It is primarily investigated for therapeutic use in liver disease
- The product is currently in the investigational stage without formal regulatory approval
Clinical Overview
Although its pharmacodynamics and precise mechanism of action have not been fully elucidated, Hydronidone’s antifibrotic properties suggest modulation of fibrogenic pathways, which may influence the deposition and remodeling of extracellular matrix components in hepatic tissue. This activity positions Hydronidone as a candidate for intervention in conditions involving liver fibrosis, including but not limited to chronic liver diseases of diverse etiologies.
Key pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion have not been comprehensively reported in the current literature. The lack of detailed ADME data limits a full understanding of the compound’s systemic behavior and dosing considerations. Safety and toxicity profiles remain under investigation given its investigational status; no definitive adverse effects have been conclusively characterized at this time.
Hydronidone is not yet approved for clinical use and is absent from marketed pharmaceutical brands. Its development status restricts its availability primarily to research contexts, including preclinical and early-phase clinical studies.
For formulation scientists and API sourcing professionals, ensuring the procurement of Hydronidone API should focus on high purity standards consistent with investigational medicinal product (IMP) guidelines. Suppliers must demonstrate robust quality control with validated analytical methods, traceability, and compliance with Good Manufacturing Practice (GMP) to support clinical trial needs and regulatory submissions. Given limited commercial production, sourcing may require engagement with specialized manufacturers experienced in novel pyridinone compounds.
Identification & chemistry
| Generic name | Hydronidone |
|---|---|
| Molecule type | Small molecule |
| CAS | 851518-71-3 |
| UNII | RXQ128313W |
| DrugBank ID | DB06299 |
Formulation & handling
- Hydronidone is a small molecule solid with moderate water solubility suitable for oral formulation.
- The compound's moderate LogP indicates balanced lipophilicity, which may influence membrane permeability and absorption.
- No specific stability or handling sensitivities reported; standard precautions for small molecule pyridinone derivatives apply.
Regulatory status
Hydronidone is a type of Antifibrotic agents
Antifibrotic agents belong to the pharmaceutical API category that focuses on treating fibrosis, a condition characterized by the excessive accumulation of fibrous connective tissue in organs. These agents target the underlying mechanisms involved in fibrosis and help prevent or slow down the progression of the disease.
One commonly used antifibrotic agent is Pirfenidone, which has shown efficacy in treating idiopathic pulmonary fibrosis (IPF). It works by inhibiting the production of pro-inflammatory and fibrotic factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). By reducing the levels of these factors, Pirfenidone helps suppress the proliferation and activation of fibroblasts, which are responsible for excessive collagen deposition in fibrotic tissues.
Another antifibrotic agent, Nintedanib, also targets IPF. It is a tyrosine kinase inhibitor that blocks the activity of various growth factor receptors, including PDGF, fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR). By inhibiting these receptors, Nintedanib disrupts the signaling pathways involved in fibrosis, thereby reducing fibroblast activation and collagen production.
These antifibrotic agents have shown promising results in clinical trials and have been approved for the treatment of IPF in several countries. They represent a significant advancement in the management of fibrotic diseases and offer hope to patients by slowing down disease progression and improving overall outcomes.
In conclusion, antifibrotic agents are a vital category of pharmaceutical APIs that target the underlying mechanisms of fibrosis. Through their action on key molecular pathways involved in fibrotic tissue deposition, these agents help reduce the accumulation of fibrous connective tissue and provide potential therapeutic benefits for patients with fibrotic diseases.
